Lal Sude Gucer

Lal Sude Gucer

Auto-generated profile, based on publicly available information

Lal Sude Gucer

Department of Infectious Diseases and Clinical Microbiology, Koç University School of Medicine, Istanbul, Türkiye

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2026 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Open access
MKMahir Kapmaz
Mahir Kapmaz
YAYağmur Nur Abik
Yağmur Nur Abik
CSCopur Sidar
Copur Sidar
PİPelin İrkören
Pelin İrkören
LGLal Sude Gücer
Lal Sude Gücer
Onder ErgonulOnder Ergonul
Onder Ergonul
A 74-year-old woman had an 8-year history of post-mastectomy lymphedema of the left upper extremity following chemotherapy and radiotherapy. She presented to three different hospitals with a 2-month history of erythema, pain

8 July 2025 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
NTNuray Tezcan
Nuray Tezcan
LGLal Sude Gucer
Lal Sude Gucer
AAAslı Aydın
Aslı Aydın
CMCisel Aydin Mericoz
Cisel Aydin Mericoz
PBPınar Bulutay
Pınar Bulutay
IKIbrahim Kulac
Ibrahim Kulac
Background: PD-L1 expression guides immunotherapy decisions in non small cell lung cancer (NSCLC), yet sample type can impact assessment accuracy. This study aimed to compare PD-L1 expression between small (biopsies, cell blocks) and large (resection) NSCLC samples, assess interobserver variability, and examine whether PD-L1 scoring trends remained stable over a multi-year period. Methods: A retrospective analysis was conducted on 494 NSCLC patients tested for PD-L1 (Ventana SP263) between 2018 and 2022. Sample type, tumor subtype, PD-L1 tumor proportion score (TPS), and reporting pathologist were recorded. Interobserver variability was analyzed based on routine diagnostic reports from different pathologists evaluating non-overlapping patient cohorts. Additionally, a subset of 43 patients had matched cell block and resection specimens collected from the same tumor, allowing direct comparison between preparations. Results: Among the 494 NSCLC specimens, 152 were large and 342 were small samples. TPS results showed 112 samples (22%) with TPS ≥ 50%, 163 (34%) with TPS 1%–49%, and 219 (44%) with TPS < 1%. No significant differences in TPS categories were observed between cell blocks and tissue samples (p = 0.176) or between small and large samples (p = 0.326). TPS distributions across different pathologists (p = 0.260) and years (p = 0.250) remained consistent. In the matched 43 specimens, TPS concordance between cell block and resection was high (κ = 0.892). Conclusion: Small biopsies and cell blocks provide reliable PD-L1 results comparable to resection specimens, supporting their use for PD-L1 testing in clinical settings to enhance timely immunotherapy access for NSCLC patients.